Combined PET/MRI Improves Treatment Decisions in Early Breast Cancer
By Lori Solomon HealthDay Reporter
FRIDAY, March 29, 2024 -- Combined positron emission tomography and magnetic resonance imaging (PET/MRI) has potential utility in the management of patients with early breast cancer, according to a study presented at the annual European Breast Cancer Conference, held from March 20 to 22 in Milan.
Rosa Di Micco, M.R.B.S., Ph.D., from IRCCS San Raffaele University and Research Hospital in Milan, and colleagues evaluated the impact of fluorodeoxyglucose PET/MRI at diagnosis on breast cancer management among 205 patients who were candidates for primary surgery.
The researchers found that PET/MRI substantially influenced treatment strategies in 27.8 percent of patients, leading to modification in clinical recommendation. These changes included primary systemic therapy or systemic therapy for metastatic or other diseases (18 patients); mastectomy instead of previously planned breast-conserving surgery (BCS; nine patients); axillary dissection or node sampling instead of sentinel node biopsy (12 patients); bilateral surgery (12 patients); and oncoplastic remodeling instead of standard BCS (six patients). Pathology showed that in 12 of these patients (21 percent), additional lesions seen on PET/MRI were not malignant. Overall, PET/MRI had a positive predictive value of 58.3 percent for detecting new foci of disease in the same breast and 45.5 percent in the contralateral breast. For visualizing multifocal breast cancer, its sensitivity was 68.4 percent and specificity was 88.9 percent. Among the 55 newly detected lesions at different sites, 37 warranted further tests (e.g., computed tomography scans, X-rays, ultrasounds, or biopsy), and this led to three diagnoses of metastatic disease, one lung cancer diagnosis, and diagnosis of 11 benign tumors and 10 benign conditions.
"Our research suggests that for patients with early breast cancer, the addition of a PET/MRI scan to standard care could help us make more informed decisions about the best treatment pathway," Di Micco said in a statement. "However, results of this technique are still affected by a high percentage of false positives and should therefore be confirmed by further testing."
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted March 2024
Read this next
Prevalence of Skin Cancer Varies for Sexual Minority, Heterosexual Adults
FRIDAY, July 19, 2024 -- With respect to their lifetime prevalence of skin cancer, sexual minority (SM) adults differ across racial and ethnic groups and among males and females...
Concussions in Children Less Likely to Be Related to Sport
FRIDAY, July 19, 2024 -- For children aged 5 through 12 years with concussion, recreation-related concussion (RRC) and non-sport or recreation-related concussion (non-SRRC) occur...
Neighborhood Disadvantage Metrics Tied to Stress Genes in Prostate Cancer
FRIDAY, July 19, 2024 -- Expression of several stress-related genes in prostate tumors is elevated among men residing in disadvantaged neighborhoods, according to a study...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.